One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
Samir Gupta, Puru Panchal, Mohsen Sadatsafavi, Parisa Ghanouni, Don Sin, Smita Pakhale, Teresa To, Zafar Zafari & Laura Nimmon for the Canadian Respiratory Research Network
doi : 10.1186/s13722-021-00283-1
Addiction Science & Clinical Practice volume 17, Article number: 1 (2022)
Chronic obstructive pulmonary disease (COPD) causes 3 million deaths each year, yet 38% of COPD patients continue to smoke. Despite proof of effectiveness and universal guideline recommendations, smoking cessation interventions are underused in practice. We sought to develop an infographic featuring personalized biomedical risk assessment through future lung function decline prediction (with vs without ongoing smoking) to both prompt and enhance clinician delivery of smoking cessation advice and pharmacotherapy, and augment patient motivation to quit.
Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial
Elizabeth R. Stevens, Lei Lei, Charles M. Cleland, Mahathi Vojjala, Omar El-Shahawy, Kenneth I. Berger, Thomas R. Kirchner & Scott E. Sherman
doi : 10.1186/s13722-021-00284-0
Addiction Science & Clinical Practice volume 17, Article number: 2 (2022)
Smoking cessation is the most effective means of slowing the decline of lung function associated with chronic obstructive pulmonary disease (COPD). While effective smoking cessation treatments are available, they are underutilized and nearly half of people with COPD continue to smoke. By addressing both nicotine and behavioral dependence, electronic cigarettes (EC) could help people with COPD reduce the harm of combustible cigarettes (CC) through reductions in number of Cigarettes per Day (CPD) or quitting CC completely. The purpose of this pilot study is to identify barriers and facilitators to the use of and assess the preliminary effectiveness of EC as a harm reduction strategy among people with COPD.
Prevalence of marijuana use in pregnant women with concurrent opioid use disorder or alcohol use in pregnancy
Kimberly Page, Cristina Murray-Krezan, Lawrence Leeman, Mary Carmody, Julia M. Stephen & Ludmila N. Bakhireva
doi : 10.1186/s13722-021-00285-z
Addiction Science & Clinical Practice volume 17, Article number: 3 (2022)
A quarter of pregnant women use alcohol, 6.5/1000 deliveries are affected by opioid use disorder (OUD), and the prevalence of cannabis use in pregnant women is increasing. However, marijuana co-exposure in polysubstance-using women is not well described.
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, Jonathan Giftos, Joshua D. Lee & Babak Tofighi
doi : 10.1186/s13722-022-00288-4
Addiction Science & Clinical Practice volume 17, Article number: 4 (2022)
Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-community treatment.
Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018
Kevin P. Conway, Dalia Khoury, Rainer Hilscher, Arnie P. Aldridge, Stephanie J. Parker & Gary A. Zarkin
doi : 10.1186/s13722-021-00282-2
Addiction Science & Clinical Practice volume 17, Article number: 5 (2022)
Medications to treat opioid use disorder (OUD) including buprenorphine products are evidence-based and cost-effective tools for combating the opioid crisis. However, limited availability to buprenorphine is pervasive in the United States (US) and may serve to exacerbate the deadly epidemic. Although prior research points to rural counties as especially needy of strategies that improve buprenorphine availability, it is important to investigate the availability of waivered providers according to treatment need as defined by the county-level rate of opioid-overdose deaths (OOD). This study examined differences in buprenorphine provider availability relative to treatment need among rural and urban counties in the US.
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans
Ismene Petrakis, Sandra A. Springer, Cynthia Davis, Elizabeth Ralevski, Lucy Gu, Robert Lew, John Hermos, Melynn Nuite, Adam J. Gordon, Thomas R. Kosten, Edward V. Nunes, Robert Rosenheck, Andrew J. Saxon, Robert Swift, Alexa Goldberg, Robert Ringer & Ryan Ferguson
doi : 10.1186/s13722-022-00286-6
Addiction Science & Clinical Practice volume 17, Article number: 6 (2022)
To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphine/naloxone (SL-BUP/NLX) are considered the standard of care for OUD including within the Veterans Healthcare Administration (VHA). However, poor retention on MOUD undermines its effectiveness. Long-acting injectable monthly buprenorphine (INJ-BUP) (e.g., Sublocade®) has the potential to improve retention and therefore reduce opioid use and overdose. Designing and conducting studies for OUD pose unique challenges. The strategies and solutions to some of these considerations in designing Cooperative Studies Program (CSP) 2014, Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE), a randomized, 20-site, clinical effectiveness trial comparing INJ-BUP to SL-BUP/NLX conducted within the VHA may provide valuable guidance for others confronted with similar investigation challenges.
